1
|
Weinberger T, Denise M, Joppich M, Fischer M, Garcia Rodriguez C, Kumaraswami K, Wimmler V, Ablinger S, Räuber S, Fang J, Liu L, Liu WH, Winterhalter J, Lichti J, Thomas L, Esfandyari D, Percin G, Matin S, Hidalgo A, Waskow C, Engelhardt S, Todica A, Zimmer R, Pridans C, Gomez Perdiguero E, Schulz C. Resident and recruited macrophages differentially contribute to cardiac healing after myocardial ischemia. eLife 2024; 12:RP89377. [PMID: 38775664 PMCID: PMC11111219 DOI: 10.7554/elife.89377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/24/2024] Open
Abstract
Cardiac macrophages are heterogenous in phenotype and functions, which has been associated with differences in their ontogeny. Despite extensive research, our understanding of the precise role of different subsets of macrophages in ischemia/reperfusion (I/R) injury remains incomplete. We here investigated macrophage lineages and ablated tissue macrophages in homeostasis and after I/R injury in a CSF1R-dependent manner. Genomic deletion of a fms-intronic regulatory element (FIRE) in the Csf1r locus resulted in specific absence of resident homeostatic and antigen-presenting macrophages, without affecting the recruitment of monocyte-derived macrophages to the infarcted heart. Specific absence of homeostatic, monocyte-independent macrophages altered the immune cell crosstalk in response to injury and induced proinflammatory neutrophil polarization, resulting in impaired cardiac remodeling without influencing infarct size. In contrast, continuous CSF1R inhibition led to depletion of both resident and recruited macrophage populations. This augmented adverse remodeling after I/R and led to an increased infarct size and deterioration of cardiac function. In summary, resident macrophages orchestrate inflammatory responses improving cardiac remodeling, while recruited macrophages determine infarct size after I/R injury. These findings attribute distinct beneficial effects to different macrophage populations in the context of myocardial infarction.
Collapse
Affiliation(s)
- Tobias Weinberger
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
- DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart AllianceMunichGermany
- Institut Pasteur, Unité Macrophages et Développement de l'Immunité, Département de Biologie du Développement et Cellules SouchesParisFrance
| | - Messerer Denise
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
| | - Markus Joppich
- LFE Bioinformatik, Department of Informatics, Ludwig Maximilian UniversityMunichGermany
| | - Maximilian Fischer
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
- DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart AllianceMunichGermany
| | - Clarisabel Garcia Rodriguez
- Institut Pasteur, Unité Macrophages et Développement de l'Immunité, Département de Biologie du Développement et Cellules SouchesParisFrance
| | - Konda Kumaraswami
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
| | - Vanessa Wimmler
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
| | - Sonja Ablinger
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
| | - Saskia Räuber
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
- Department of Neurology, Medical Faculty, Heinrich Heine University of DüsseldorfDüsseldorfGermany
| | - Jiahui Fang
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
| | - Lulu Liu
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
| | - Wing Han Liu
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
| | - Julia Winterhalter
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
| | - Johannes Lichti
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
| | - Lukas Thomas
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
- DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart AllianceMunichGermany
| | - Dena Esfandyari
- DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart AllianceMunichGermany
- Institute of Pharmacology and Toxicology, Technical University MunichMunichGermany
| | - Guelce Percin
- Immunology of Aging, Leibniz-Institute on Aging - Fritz-Lipmann-Institute (FLI)JenaGermany
| | - Sandra Matin
- Area of Cell & Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos IIIMadridSpain
| | - Andrés Hidalgo
- Area of Cell & Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos IIIMadridSpain
- Vascular Biology and Therapeutics Program and Department of Immunobiology, Yale University School of MedicineNew HavenUnited States
| | - Claudia Waskow
- Immunology of Aging, Leibniz-Institute on Aging - Fritz-Lipmann-Institute (FLI)JenaGermany
- Faculty of Biological Sciences, Friedrich-Schiller-UniversityJenaGermany
| | - Stefan Engelhardt
- DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart AllianceMunichGermany
- Institute of Pharmacology and Toxicology, Technical University MunichMunichGermany
| | - Andrei Todica
- Department of Nuclear Medicine, Ludwig Maximilian UniversityMunichGermany
| | - Ralf Zimmer
- LFE Bioinformatik, Department of Informatics, Ludwig Maximilian UniversityMunichGermany
| | - Clare Pridans
- Simons Initiative for the Developing Brain, Centre for Discovery Brain Sciences, University of EdinburghEdinburghUnited Kingdom
- University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research InstituteEdinburghUnited Kingdom
| | - Elisa Gomez Perdiguero
- Institut Pasteur, Unité Macrophages et Développement de l'Immunité, Département de Biologie du Développement et Cellules SouchesParisFrance
| | - Christian Schulz
- Medical Clinic I., Department of Cardiology, University Hospital, Ludwig Maximilian UniversityMunichGermany
- Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine UniversityMunichGermany
- DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart AllianceMunichGermany
- Department of Immunopharmacology, Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg UniversityMannheimGermany
| |
Collapse
|
2
|
Detection of apoptosis by [ 18F]ML-10 after cardiac ischemia-reperfusion injury in mice. Ann Nucl Med 2023; 37:34-43. [PMID: 36306025 PMCID: PMC9813199 DOI: 10.1007/s12149-022-01801-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Accepted: 10/20/2022] [Indexed: 01/09/2023]
Abstract
OBJECTIVE Myocardial infarction leads to ischemic heart disease and cell death, which is still a major obstacle in western society. In vivo imaging of apoptosis, a defined cascade of cell death, could identify myocardial tissue at risk. METHODS Using 2-(5-[18F]fluoropentyl)-2-methyl-malonic acid ([18F]ML-10) in autoradiography and positron emission tomography (PET) visualized apoptosis in a mouse model of transient ligation of the left anterior descending (LAD) artery. 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET imaging indicated the defect area. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) histology stain indicated cardiac apoptosis. RESULTS [18F]ML-10 uptake was evident in the ischemic area after transient LAD ligation in ex vivo autoradiography and in vivo PET imaging. Detection of [18F]ML-10 is in line with the defect visualized by [18F]FDG and the histological approach of TUNEL staining. CONCLUSION The tracer [18F]ML-10 is suitable for detecting apoptosis after transient LAD ligation in mice.
Collapse
|
3
|
Comparison of transient and permanent LAD ligation in mice using 18F-FDG PET imaging. Ann Nucl Med 2022; 36:533-543. [PMID: 35355159 PMCID: PMC9132804 DOI: 10.1007/s12149-022-01734-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Accepted: 02/27/2022] [Indexed: 11/10/2022]
Abstract
Objective Animal models for myocardial injuries represent important cornerstones in cardiovascular research to monitor the pathological processes and therapeutic approaches. We investigated the association of 18F-FDG derived left ventricular metabolic volume (LVMV), defect area and cardiac function in mice after permanent or transient ligation of the left anterior descending artery (LAD). Methods Serial non-invasive ECG-gated 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (18F-FDG PET) after permanent or transient LAD ligation enabled a longitudinal in vivo correlation of 18F-FDG derived left ventricular metabolic volume to functional parameters and myocardial defect. Results The LVMV shows a more prominent drop after permanent than transient LAD ligation and recovers after 30 days. The loss of LVMV correlates with the defect area assessed by QPS software. Cardiac function parameters (e.g., EDV, ESV, SV) by the QGS software positively correlate with LVMV after permanent and transient LAD ligation. Conclusions This study provides novel insight into 18F-FDG derived LVMV after permanent and transient LAD ligation by longitudinal in 18F-FDG PET imaging and underlines the associations of the FDG derived parameter and cardiac function. Supplementary Information The online version contains supplementary material available at 10.1007/s12149-022-01734-8.
Collapse
|
4
|
Fischer M, Olivier J, Lindner S, Zacherl MJ, Massberg S, Bartenstein P, Ziegler S, Brendel M, Lehner S, Boening G, Todica A. Detection of cardiac apoptosis by [ 18F]ML-10 in a mouse model of permanent LAD ligation. Mol Imaging Biol 2022; 24:666-674. [PMID: 35352214 PMCID: PMC9296384 DOI: 10.1007/s11307-022-01718-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 03/06/2022] [Accepted: 03/07/2022] [Indexed: 11/26/2022]
Abstract
Purpose The loss of viable cardiac cells and cell death by myocardial infarction (MI) is still a significant obstacle in preventing deteriorating heart failure. Imaging of apoptosis, a defined cascade to cell death, could identify areas at risk. Procedures Using 2-(5-[18F]fluoropentyl)-2-methyl-malonic acid ([18F]ML-10) in autoradiography and positron emission tomography (PET) visualized apoptosis in murine hearts after permanent ligation of the left anterior descending artery (LAD) inducing myocardial infarction (MI). 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET imaging localized the infarct area after MI. Histology by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining validated apoptosis in the heart. Results Accumulation of [18F]ML-10 was evident in the infarct area after permanent ligation of the LAD in autoradiography and PET imaging. Detection of apoptosis by [18F]ML-10 is in line with the defect visualized by [18F]FDG and the histological approach. Conclusion [18F]ML-10 could be a suitable tracer for apoptosis imaging in a mouse model of permanent LAD ligation. Supplementary Information The online version contains supplementary material available at 10.1007/s11307-022-01718-0.
Collapse
Affiliation(s)
- Maximilian Fischer
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, 80802, Munich, Germany
| | - Jessica Olivier
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Simon Lindner
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Mathias J Zacherl
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Steffen Massberg
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, 80802, Munich, Germany
| | - Peter Bartenstein
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sibylle Ziegler
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Matthias Brendel
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sebastian Lehner
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
- Ambulatory Healthcare Center Dr. Neumaier & Colleagues, Radiology, Nuclear Medicine, Radiation Therapy, Regensburg, Germany
| | - Guido Boening
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Andrei Todica
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
- DIE RADIOLOGIE, Munich, Germany.
| |
Collapse
|
5
|
Zacherl MJ, Todica A, Wängler C, Schirrmacher R, Hajebrahimi MA, Pircher J, Li X, Lindner S, Brendel M, Bartenstein P, Massberg S, Brunner S, Lehner S, Hacker M, Huber BC. Molecular imaging of cardiac CXCR4 expression in a mouse model of acute myocardial infarction using a novel 68Ga-mCXCL12 PET tracer. J Nucl Cardiol 2021; 28:2965-2975. [PMID: 32676914 PMCID: PMC8709820 DOI: 10.1007/s12350-020-02262-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 06/08/2020] [Indexed: 01/16/2023]
Abstract
BACKGROUND The chemokine receptor CXCR4 and its ligand CXCL12 have been shown to be a possible imaging and therapeutic target after myocardial infarction (MI). The murine-based and mouse-specific 68Ga-mCXCL12 PET tracer could be suitable for serial in vivo quantification of cardiac CXCR4 expression in a murine model of MI. METHODS AND RESULTS At days 1-6 after MI, mice were intravenously injected with 68Ga-mCXCL12. Autoradiography was performed and the infarct-to-remote ratio (I/R) was determined. In vivo PET imaging with 68Ga-mCXCL12 was conducted on days 1-6 after MI and the percentage of the injected dose (%ID/g) of the tracer uptake in the infarct area was calculated. 18F-FDG-PET was performed for anatomical landmarking. Ex vivo autoradiography identified CXCR4 upregulation in the infarct region with an increasing I/R after 12 hours (1.4 ± 0.3), showing a significant increase until day 2 (4.5 ± 0.6), followed by a plateau phase (day 4) and decrease after 10 days (1.3 ± 1.0). In vivo PET imaging identified similar CXCR4 upregulation in the infarct region which peaked around day 3 post MI (9.7 ± 5.0 %ID/g) and then subsequently decreased by day 6 (2.8 ± 1.0 %ID/g). CONCLUSION Noninvasive molecular imaging of cardiac CXCR4 expression using a novel, murine-based, and specific 68Ga-mCXCL12 tracer is feasible both ex vivo and in vivo.
Collapse
Affiliation(s)
| | - Andrei Todica
- Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany
| | - Carmen Wängler
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany
| | - Ralf Schirrmacher
- Department of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, AB, Canada
| | | | - Joachim Pircher
- Department of Cardiology, University Hospital of Munich, LMU Munich, Munich, Germany
- German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Xiang Li
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Simon Lindner
- Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany
| | - Matthias Brendel
- Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany
| | - Peter Bartenstein
- Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany
| | - Steffen Massberg
- Department of Cardiology, University Hospital of Munich, LMU Munich, Munich, Germany
- German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Stefan Brunner
- Department of Cardiology, University Hospital of Munich, LMU Munich, Munich, Germany
| | - Sebastian Lehner
- Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany
- Ambulatory Healthcare Center Dr. Neumaier & Colleagues, Radiology, Nuclear Medicine, Radiation Therapy, Regensburg, Germany
| | - Marcus Hacker
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
| | - Bruno C Huber
- Department of Cardiology, University Hospital of Munich, LMU Munich, Munich, Germany
| |
Collapse
|
6
|
Sari N, Katanasaka Y, Sugiyama Y, Miyazaki Y, Sunagawa Y, Funamoto M, Shimizu K, Shimizu S, Hasegawa K, Morimoto T. Alpha Mangostin Derived from Garcinia magostana Linn Ameliorates Cardiomyocyte Hypertrophy and Fibroblast Phenotypes in Vitro. Biol Pharm Bull 2021; 44:1465-1472. [PMID: 34602555 DOI: 10.1248/bpb.b21-00294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cardiac hypertrophy and fibrosis are significant risk factors for chronic heart failure (HF). Since pharmacotherapy agents targeting these processes have not been established, we investigated the effect of alpha-magostin (α-man) on cardiomyocyte hypertrophy and fibrosis in vitro. Primary cultured cardiomyocytes and cardiac fibroblasts were prepared from neonatal rats. After α-man treatment, phenylephrine (PE) and transforming growth factor-beta (TGF-β) were added to the cardiomyocytes and cardiac fibroblasts to induce hypertrophic and fibrotic responses, respectively. Hypertrophic responses were assessed by measuring the cardiomyocyte surface area and hypertrophic gene expression levels. PE-induced phosphorylation of Akt, extracellular signal-regulated kinase (ERK)1/2, and p38 was examined by Western blotting. Fibrotic responses were assessed by measuring collagen synthesis, fibrotic gene expression levels, and myofibroblast differentiation. In addition, TGF-β-induced reactive oxygen species (ROS) production was investigated. In cultured cardiomyocytes, α-man significantly suppressed PE-induced increases in the cardiomyocyte surface area, and the mRNA levels (atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP)). Treatment with α-man significantly suppressed PE-induced Akt phosphorylation, but not ERK and p38 phosphorylation. In cultured cardiac fibroblasts, α-man significantly suppressed TGF-β-induced increases in L-proline incorporation, mRNA levels (POSTN and alpha-smooth muscle actin (α-SMA)), and myofibroblast differentiation. Additionally, it significantly inhibited TGF-β-induced reduced nicotinamide adenine dinucleotide phosphate oxidase4 (NOX4) expression and ROS production in cardiac fibroblasts. Treatment with α-man significantly ameliorates hypertrophy by inhibiting Akt phosphorylation in cardiomyocytes and fibrosis by inhibiting NOX4-generating ROS in fibroblasts. These findings suggest that α-man is a possible natural product for the prevention of cardiac hypertrophy and fibrosis.
Collapse
Affiliation(s)
- Nurmila Sari
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka
| | - Yasufumi Katanasaka
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center.,Shizuoka General Hospital
| | - Yuga Sugiyama
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka
| | - Yusuke Miyazaki
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center.,Shizuoka General Hospital
| | - Yoichi Sunagawa
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center.,Shizuoka General Hospital
| | - Masafumi Funamoto
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center
| | - Kana Shimizu
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center
| | - Satoshi Shimizu
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center
| | - Koji Hasegawa
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center
| | - Tatsuya Morimoto
- Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka.,Clinical Research Institute, Division of Translational Research, National Hospital Organization Kyoto Medical Center.,Shizuoka General Hospital
| |
Collapse
|
7
|
Fischer M, Zacherl MJ, Weckbach L, Paintmayer L, Weinberger T, Stark K, Massberg S, Bartenstein P, Lehner S, Schulz C, Todica A. Cardiac 18F-FDG Positron Emission Tomography: An Accurate Tool to Monitor In vivo Metabolic and Functional Alterations in Murine Myocardial Infarction. Front Cardiovasc Med 2021; 8:656742. [PMID: 34113662 PMCID: PMC8185215 DOI: 10.3389/fcvm.2021.656742] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 05/04/2021] [Indexed: 12/28/2022] Open
Abstract
Cardiac monitoring after murine myocardial infarction, using serial non-invasive cardiac 18F-FDG positron emissions tomography (PET) represents a suitable and accurate tool for in vivo studies. Cardiac PET imaging enables tracking metabolic alterations, heart function parameters and provides correlations of the infarct size to histology. ECG-gated 18F-FDG PET scans using a dedicated small-animal PET scanner were performed in mice at baseline, 3, 14, and 30 days after myocardial infarct (MI) by permanent ligation of the left anterior descending (LAD) artery. The percentage of the injected dose per gram (%ID/g) in the heart, left ventricular metabolic volume (LVMV), myocardial defect, and left ventricular function parameters: end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV), and the ejection fraction (EF%) were estimated. PET assessment of the defect positively correlates with post-infarct histology at 3 and 30 days. Infarcted murine hearts show an immediate decrease in LVMV and an increase in %ID/g early after infarction, diminishing in the remodeling process. This study of serial cardiac PET scans provides insight for murine myocardial infarction models by novel infarct surrogate parameters. It depicts that serial PET imaging is a valid, accurate, and multimodal non-invasive assessment.
Collapse
Affiliation(s)
- Maximilian Fischer
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
| | - Mathias J Zacherl
- Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Ludwig Weckbach
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
| | - Lisa Paintmayer
- Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Tobias Weinberger
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
| | - Konstantin Stark
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
| | - Steffen Massberg
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
| | - Peter Bartenstein
- Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Sebastian Lehner
- Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.,Ambulatory Healthcare Center Dr. Neumaier & Colleagues, Radiology, Nuclear Medicine, Radiation Therapy, Regensburg, Germany
| | - Christian Schulz
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
| | - Andrei Todica
- Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| |
Collapse
|
8
|
Fischer M, Zacherl MJ, Weinberger T, Weckbach L, Huber B, Schulz C, Massberg S, Bartenstein P, Lehner S, Todica A. Comparison of metabolic and functional parameters using cardiac 18F-FDG-PET in early to mid-adulthood male and female mice. EJNMMI Res 2021; 11:7. [PMID: 33464447 PMCID: PMC7815863 DOI: 10.1186/s13550-021-00748-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Accepted: 01/05/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND In this descriptive study of male and female mice at different weeks of age, we use serial non-invasive cardiac 18F-FDG-PET scans to follow up on metabolic alterations, heart function parameters, and the ECG of both sexes in early to mid-adulthood. METHODS ECG-gated 18F-FDG-PET scans were performed in mice on 10, 14, and 18 weeks of age, using a dedicated small-animal PET scanner. The percentage of the injected activity per gram (%IA/g) in the heart, left ventricular metabolic volume (LVMV), myocardial viability and left ventricular function parameters: end-diastolic (EDV), end-systolic (ESV), stroke volume (SV), and the ejection fraction (EF%) were estimated. RESULTS Compared to their age-matched female counterpart, male mice showed a constant increase in LVMV and ventricular volume during the follow-up. In contrast, female mice remain stable after ten weeks of age. Furthermore, male mice showed lower heart rates, positive correlation with cardiac %IA/g, and negative correlation with LVMV. CONCLUSION In this study of serial cardiac PET scans, we provide insight for basic murine research models, showing that mice gender and age show distinct cardiac metabolisms. These physiologic alterations need to be considered when planning in vivo injury models to avoid potential pitfalls.
Collapse
Affiliation(s)
- Maximilian Fischer
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
| | - Mathias J Zacherl
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Tobias Weinberger
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
| | - Ludwig Weckbach
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
| | - Bruno Huber
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
| | - Christian Schulz
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
| | - Steffen Massberg
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany
| | - Peter Bartenstein
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sebastian Lehner
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.,Ambulatory Healthcare Center Dr. Neumaier & Colleagues, Radiology, Nuclear Medicine, Radiation Therapy, Regensburg, Germany
| | - Andrei Todica
- Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| |
Collapse
|
9
|
18F-FDG PET-Based Imaging of Myocardial Inflammation Following Acute Myocardial Infarction in a Mouse Model. Int J Mol Sci 2020; 21:ijms21093340. [PMID: 32397287 PMCID: PMC7246846 DOI: 10.3390/ijms21093340] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 05/05/2020] [Accepted: 05/06/2020] [Indexed: 01/13/2023] Open
Abstract
Cellular inflammation is an integral part of the healing process following acute myocardial infarction and has been under intense investigation for both therapeutic and prognostic approaches. Monocytes and macrophages are metabolically highly active and show increased uptake rates of glucose and its analog, 18F-FDG. Yet, the specific allocation of the radioactivity to the inflammatory cells via positron emission tomography (PET) imaging requires the suppression of glucose metabolism in viable myocardium. In mice, the most important model organism in basic research, this can be achieved by the application of ketamine/xylazine (KX) for anesthesia instead of isoflurane. Yet, while the consensus exists that glucose metabolism is effectively suppressed, a strategy for reproducible image analysis is grossly lacking and causes uncertainty concerning data interpretation. We introduce a simple strategy for systematic image analysis, which is a prerequisite to evaluate therapies targeting myocardial inflammation. Mice underwent permanent occlusion of the left anterior descending artery (LAD), inducing an acute myocardial infarction (MI). Five days after MI induction, 10MBq 18F-FDG was injected intravenously and a static PET/CT scan under ketamine/xylazine anesthesia was performed. For image reconstruction, we used an algorithm based on three-dimensional ordered subsets expectation maximization (3D-OSEM) followed by three-dimensional ordinary Poisson maximum a priori (MAP) reconstruction. Using this approach, high focal tracer uptake was typically located in the border zone of the infarct by visual inspection. To precisely demarcate the border zone for reproducible volume of interest (VOI) positioning, our protocol relies on positioning VOIs around the whole left ventricle, the inferobasal wall and the anterolateral wall guided by anatomical landmarks. This strategy enables comparable data in mouse studies, which is an important prerequisite for using a PET-based assessment of myocardial inflammation as a prognostic tool in therapeutic applications.
Collapse
|
10
|
Glasenapp A, Derlin K, Wang Y, Bankstahl M, Meier M, Wollert KC, Bengel FM, Thackeray JT. Multimodality Imaging of Inflammation and Ventricular Remodeling in Pressure-Overload Heart Failure. J Nucl Med 2019; 61:590-596. [PMID: 31653713 DOI: 10.2967/jnumed.119.232488] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 09/25/2019] [Indexed: 12/28/2022] Open
Abstract
Inflammation contributes to ventricular remodeling after myocardial ischemia, but its role in nonischemic heart failure is poorly understood. Local tissue inflammation is difficult to assess serially during pathogenesis. Although 18F-FDG accumulates in inflammatory leukocytes and thus may identify inflammation in the myocardial microenvironment, it remains unclear whether this imaging technique can isolate diffuse leukocytes in pressure-overload heart failure. We aimed to evaluate whether inflammation with 18F-FDG can be serially imaged in the early stages of pressure-overload-induced heart failure and to compare the time course with functional impairment assessed by cardiac MRI. Methods: C57Bl6/N mice underwent transverse aortic constriction (TAC) (n = 22), sham surgery (n = 12), or coronary ligation as an inflammation-positive control (n = 5). MRI assessed ventricular geometry and contractile function at 2 and 8 d after TAC. Immunostaining identified the extent of inflammatory leukocyte infiltration early in pressure overload. 18F-FDG PET scans were acquired at 3 and 7 d after TAC, under ketamine-xylazine anesthesia to suppress cardiomyocyte glucose uptake. Results: Pressure overload evoked rapid left ventricular dilation compared with sham (end-systolic volume, day 2: 40.6 ± 10.2 μL vs. 23.8 ± 1.7 μL, P < 0.001). Contractile function was similarly impaired (ejection fraction, day 2: 40.9% ± 9.7% vs. 59.2% ± 4.4%, P < 0.001). The severity of contractile impairment was proportional to histology-defined myocardial macrophage density on day 8 (r = -0.669, P = 0.010). PET imaging identified significantly higher left ventricular 18F-FDG accumulation in TAC mice than in sham mice on day 3 (10.5 ± 4.1 percentage injected dose [%ID]/g vs. 3.8 ± 0.9 %ID/g, P < 0.001) and on day 7 (7.8 ± 3.7 %ID/g vs. 3.0 ± 0.8 %ID/g, P = 0.006), though the efficiency of cardiomyocyte suppression was variable among TAC mice. The 18F-FDG signal correlated with ejection fraction (r = -0.75, P = 0.01) and ventricular volume (r = 0.75, P < 0.01). Western immunoblotting demonstrated a 60% elevation of myocardial glucose transporter 4 expression in the left ventricle at 8 d after TAC, indicating altered glucose metabolism. Conclusion: TAC induces rapid changes in left ventricular geometry and contractile function, with a parallel modest infiltration of inflammatory macrophages. Metabolic remodeling overshadows inflammatory leukocyte signal using 18F-FDG PET imaging. More selective inflammatory tracers are requisite to identify the diffuse local inflammation in pressure overload.
Collapse
Affiliation(s)
- Aylina Glasenapp
- Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany.,Department of Radiology, Hannover Medical School, Hannover, Germany
| | - Katja Derlin
- Department of Radiology, Hannover Medical School, Hannover, Germany
| | - Yong Wang
- Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; and
| | - Marion Bankstahl
- Central Laboratory Animal Facility and Institute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany
| | - Martin Meier
- Central Laboratory Animal Facility and Institute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany
| | - Kai C Wollert
- Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; and
| | - Frank M Bengel
- Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany
| | - James T Thackeray
- Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany
| |
Collapse
|